Around the world, tuberculosis (TB) remains one of the most common causes of morbidity and mortality. The molecular mechanism ofMycobacterium tuberculosis(Mtb) infection is still unclear. Extracellular vesicles (EVs) play a key role in the onset and progression of many disease states and can serve as effective biomarkers or therapeutic targets for the identification and treatment of TB patients. We analysed the expression profile to better clarify the EVs characteristics of TB and explored potential diagnostic markers to distinguish TB from healthy control (HC). Twenty EVs‐related differentially expressed genes (DEGs) were identified, and 17 EVs‐related DEGs were up‐regulated and three DEGs were down‐regulated in TB samples, which were related to immune cells. Using machine learning, a nine EVs‐related gene signature was identified and two EVs‐related subclusters were defined. The single‐cell RNA sequence (scRNA‐seq) analysis further confirmed that these hub genes might play important roles in TB pathogenesis. The nine EVs‐related hub genes had excellent diagnostic values and accurately estimated TB progression. TB's high‐risk group had significantly enriched immune‐related pathways, and there were substantial variations in immunity across different groups. Furthermore, five potential drugs were predicted for TB using CMap database. Based on the EVs‐related gene signature, the TB risk model was established through a comprehensive analysis of different EV patterns, which can accurately predict TB. These genes could be used as novel biomarkers to distinguish TB from HC. These findings lay the foundation for further research and design of new therapeutic interventions aimed at treating this deadly infectious disease.
Invasion and metastasis are major causes of mortality in breast cancer (BRCA) patients. LHPP, known for its tumor‐suppressive effects, has an undefined role in BRCA. We found reduced LHPP protein in BRCA tissues, with lower levels correlating with poor patient outcomes. In vitro studies show LHPP inhibits BRCA cell proliferation, migration, invasion, and stemness. In vivo xenograft models support LHPP's role in curbing tumorigenesis and lung metastasis. Mechanistically, LHPP interacts with ERK and P38 MAPK, leading to their dephosphorylation and suppression of the MAPK pathway. We also reveal ETS1, a MAPK effector, repressing LHPP mRNA transcription, suggesting a LHPP‐P38 MAPK/ERK‐ETS1 negative feedback loop as a key regulatory mechanism in controlling BRCA invasion and metastasis.
Background Breast cancer (BC) continues to be a predominant cause of cancer-related deaths among women globally, highlighting the complexity of the disease, its propensity for metastasis, and resistance to conventional therapies. The discovery of clinical biomarkers and therapeutic targets is crucial for advancing BC treatment strategies. Methods We conducted a Transcriptome-Wide Association Study (TWAS) and Weighted Gene Co-expression Network Analysis (WGCNA) to pinpoint genes associated with BC, with GSTM4 emerging as a candidate tumor suppressor. To further elucidate GSTM4’s role, we analyzed its mRNA and protein expression using multiple databases. The prognostic significance of GSTM4 was evaluated using KM-Plotter tools, while its epigenetic profile was examined through GSCA. Protein–Protein Interaction (PPI) networks were constructed with GeneMANIA and STRING to explore GSTM4’s functional interactions. The ssGSEA algorithm and TIMER were employed to link GSTM4 with the immune context of BC. Single-cell RNA sequencing from GSE148673 was analyzed to investigate GSTM4’s influence on the tumor immune microenvironment. In vitro experiments were designed to assess GSTM4’s impact on BC cell behavior. Results GSTM4 expression is diminished in BC tissues and is positively linked to better patient outcomes. Epigenetic studies indicate that GSTM4 silencing may partly result from promoter deletion mutation. The PPI network and enrichment analysis are consistent with GSTM4’s multifaceted role in glutathione metabolism, detoxification, antioxidant defense, and oxidoreductase reactions. GSTM4 expression shows a negative correlation with immune checkpoint gene expression and is associated with an enhanced antitumor immune response in BC as well as increased sensitivity to anticancer drugs. Single-cell RNA sequencing analysis suggests a association of GSTM4 with the prevention of epithelial transformation, the mitigation of BC cell malignancy, and the promotion of tumor microenvironment interactions. In vitro studies confirm GSTM4’s inhibitory effects on BC cell proliferation, invasion, and stemness. Conclusion Integrated analyses identify GSTM4 as a potential tumor suppressor and prognostic biomarker in BC, suggesting its promise for advancing therapies.